Intellia Therapeutics (NTLA) Retained Earnings (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Retained Earnings for 12 consecutive years, with -$2.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 254246.17% year-over-year to -$2.7 billion; the TTM figure through Mar 2026 stood at -$2.7 billion (down 254246.17% YoY), while the FY2025 annual figure was -$2.6 billion, down 18.95% from the prior year.
• Retained Earnings retreated to -$2.7 billion in Q1 2026 per NTLA's latest filing, from -$2.6 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $1.1 million in Q1 2025 and bottomed at -$2.7 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$1.1 billion across 5 years, with a median of -$1.1 billion in 2022.
• Annual changes were most pronounced in 2022 — Retained Earnings slumped 7311830.77% — and 2025, when it surged 211.62%.
• Intellia Therapeutics' Retained Earnings stood at -$1.2 billion in 2022, then tumbled by 40.88% to -$1.7 billion in 2023, then tumbled by 31.3% to -$2.2 billion in 2024, then retreated by 18.95% to -$2.6 billion in 2025, then declined by 3.72% to -$2.7 billion in 2026.
• Business Quant data shows NTLA's Retained Earnings at -$2.7 billion in Q1 2026, -$2.6 billion in Q4 2025, and -$2.5 billion in Q3 2025.